These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
4. [Role of ACE2 in COVID-19]. Imai Y Nihon Yakurigaku Zasshi; 2022; 157(2):115-118. PubMed ID: 35228442 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review. Singh B; Singh D; Verma V; Yadav R; Kumar R J Pharm Anal; 2022 Apr; 12(2):215-220. PubMed ID: 34934510 [TBL] [Abstract][Full Text] [Related]
6. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Verdecchia P; Cavallini C; Spanevello A; Angeli F Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612 [TBL] [Abstract][Full Text] [Related]
7. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
9. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses. Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. Kuba K; Yamaguchi T; Penninger JM Front Immunol; 2021; 12():732690. PubMed ID: 35003058 [TBL] [Abstract][Full Text] [Related]
11. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
12. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
13. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2. Rowland R; Brandariz-Nuñez A Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876 [TBL] [Abstract][Full Text] [Related]
15. The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure. Angeli F; Zappa M; Reboldi G; Gentile G; Trapasso M; Spanevello A; Verdecchia P Eur J Intern Med; 2023 Mar; 109():12-21. PubMed ID: 36528504 [TBL] [Abstract][Full Text] [Related]
16. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480 [TBL] [Abstract][Full Text] [Related]
17. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2). Xiang Y; Wang M; Chen H; Chen L Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936 [TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells. Verma D; Church TM; Swaminathan S J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]